The battery-powered and portable medical device uses advanced quantum principles to measure, display and store electromagnetic fluctuations caused by heart activity through a three to five-minute scan.

The scan is said to rule out significant ischaemic heart disease such as heart attacks.

Vitalscan will help clinical practitioners to prevent heart-related problems in patients, in addition to avoiding healthy patients undergoing chest pain triage process that includes different diagnostic tests such as multiple ECGs and cardiac biomarker blood tests.

The company will also commence a multi-centre clinical trial for the Vitalscan device at four centers, including Bristol, Sheffield, Leicester and Nottingham.

In addition, the firm will carry out second stage trail at three centres in the US, including Mayo Clinic Rochester, Cincinnati and Baylor Texas.

Creavo Medical Technologies CEO Steve Parker said: “At a time when the NHS is facing unprecedented pressures, Vitalscan has the potential to radically disrupt the current process for patients entering emergency departments with chest pain, bringing millions of pounds of savings to the NHS a week, easing pressure on bed space in A&E and reducing patient anxiety.

“The CE mark means that we can now look forward to building momentum with the launch of our multi-centre clinical study, testing the device in four of the busiest A&E departments in the UK and in the US.”

Founded in 2014, Creavo Medical operates facilities in Leeds and Coventry, UK.